UY38930A - Compuestos moduladores alostéricos positivos para gabaa, métodos de fabricación y sus usos - Google Patents
Compuestos moduladores alostéricos positivos para gabaa, métodos de fabricación y sus usosInfo
- Publication number
- UY38930A UY38930A UY0001038930A UY38930A UY38930A UY 38930 A UY38930 A UY 38930A UY 0001038930 A UY0001038930 A UY 0001038930A UY 38930 A UY38930 A UY 38930A UY 38930 A UY38930 A UY 38930A
- Authority
- UY
- Uruguay
- Prior art keywords
- manufacturing methods
- positive allosteric
- allosteric modulator
- modulator compounds
- gabaa positive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Abstract
En la presente se describen polimorfos que comprenden 2’,6-difluoro-5’-[3-(1-hidroxi-1-metiletil)-imidazo[1,2-b][1,2,4]triazin-7-il]bifenill-2-carbonitrilo (TPA023B) o sales de estos. En un aspecto, en la presente se describe una sal polimórfica cristalina o cocristal de TPA023B con ácido fosfórico. En otro aspecto, se describe en la presente una sal polimórfica cristalina o cocristal de TPA023B con ácido sulfúrico. También se describen en la presente métodos para prepararlos y usarlos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962924276P | 2019-10-22 | 2019-10-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY38930A true UY38930A (es) | 2021-05-31 |
Family
ID=75619360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001038930A UY38930A (es) | 2019-10-22 | 2020-10-22 | Compuestos moduladores alostéricos positivos para gabaa, métodos de fabricación y sus usos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230017378A1 (es) |
| EP (1) | EP4048672A4 (es) |
| JP (1) | JP2022553718A (es) |
| KR (1) | KR20220087461A (es) |
| CN (1) | CN114981266A (es) |
| AU (1) | AU2020371635A1 (es) |
| BR (1) | BR112022007522A2 (es) |
| CA (1) | CA3154222A1 (es) |
| CL (1) | CL2022000980A1 (es) |
| IL (1) | IL292340A (es) |
| MX (1) | MX2022004642A (es) |
| TW (1) | TW202128697A (es) |
| UY (1) | UY38930A (es) |
| WO (1) | WO2021081147A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1343788B1 (en) * | 2000-11-10 | 2005-11-23 | MERCK SHARP & DOHME LTD. | Imidazo-triazine derivatives as ligands for gaba receptors |
| GB0117277D0 (en) * | 2001-07-16 | 2001-09-05 | Merck Sharp & Dohme | Therapeutic agents |
| WO2015189744A1 (en) * | 2014-06-12 | 2015-12-17 | Pfizer Limited | Imidazopyridazine derivatives as modulators of the gabaa receptor activity. |
| MX2020010878A (es) * | 2018-04-18 | 2021-01-29 | Neurocycle Therapeutics Inc | Compuestos moduladores alostericos positivos gabaa, metodos de preparacion y usos de los mismos. |
| IL292343A (en) * | 2019-10-23 | 2022-06-01 | Neurocycle Therapeutics Inc | Treatment of epileptic states with gabaa receptor modulators |
-
2020
- 2020-10-22 CA CA3154222A patent/CA3154222A1/en active Pending
- 2020-10-22 MX MX2022004642A patent/MX2022004642A/es unknown
- 2020-10-22 IL IL292340A patent/IL292340A/en unknown
- 2020-10-22 CN CN202080074393.4A patent/CN114981266A/zh active Pending
- 2020-10-22 US US17/770,928 patent/US20230017378A1/en active Pending
- 2020-10-22 TW TW109136703A patent/TW202128697A/zh unknown
- 2020-10-22 UY UY0001038930A patent/UY38930A/es unknown
- 2020-10-22 EP EP20879254.9A patent/EP4048672A4/en active Pending
- 2020-10-22 JP JP2022523889A patent/JP2022553718A/ja active Pending
- 2020-10-22 WO PCT/US2020/056750 patent/WO2021081147A1/en active Application Filing
- 2020-10-22 BR BR112022007522A patent/BR112022007522A2/pt unknown
- 2020-10-22 KR KR1020227014893A patent/KR20220087461A/ko unknown
- 2020-10-22 AU AU2020371635A patent/AU2020371635A1/en active Pending
-
2022
- 2022-04-19 CL CL2022000980A patent/CL2022000980A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022004642A (es) | 2022-05-10 |
| KR20220087461A (ko) | 2022-06-24 |
| IL292340A (en) | 2022-06-01 |
| BR112022007522A2 (pt) | 2022-07-12 |
| TW202128697A (zh) | 2021-08-01 |
| AU2020371635A1 (en) | 2022-06-09 |
| WO2021081147A1 (en) | 2021-04-29 |
| EP4048672A1 (en) | 2022-08-31 |
| CA3154222A1 (en) | 2021-04-29 |
| CN114981266A (zh) | 2022-08-30 |
| CL2022000980A1 (es) | 2023-01-20 |
| EP4048672A4 (en) | 2023-11-15 |
| US20230017378A1 (en) | 2023-01-19 |
| JP2022553718A (ja) | 2022-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002663A1 (es) | Compuestos moduladores alostéricos positivos gabaa, métodos de preparación y usos de los mismos | |
| CL2023001299A1 (es) | Procedimiento de fabricación de un inhibidor pd-1/pd-l1 y de sus sales y formas cristalinas de los mismos. | |
| CL2020002848A1 (es) | Sales de un inhibidor de fgfr. | |
| CL2020002839A1 (es) | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas. | |
| CO2022008359A2 (es) | Derivados de un inhibidor de fgfr | |
| CU20180152A7 (es) | Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| CL2018001484A1 (es) | Dinucleotidas de purino ciclico como moduladores de estimulador de genes de interferon (sting). | |
| CL2020002530A1 (es) | Ciano tienotriazolpirazinas y usos de las mismas.(divisional de solicitud 621-2018) | |
| CR20190483A (es) | Compuestos de heteroarilo bicíclicos 6-6 fusionados y su uso como inhibidores de lats | |
| ES2611343T3 (es) | Análogos de 3-alquinil pirazolopirimidina funcionalizada como bases universales y métodos de uso | |
| AR083358A1 (es) | Compuestos de furo[3,2-d]pirimidina | |
| UY35023A (es) | Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso | |
| CR20140133A (es) | Compuestos de piridazinona y sus usos como inhibidores de daao | |
| UY38930A (es) | Compuestos moduladores alostéricos positivos para gabaa, métodos de fabricación y sus usos | |
| CL2019002079A1 (es) | Sales del inhibidor de pim quinasa; útiles en el tratamiento del cáncer. (divisional solicitud 201800611) | |
| PE20230323A1 (es) | Compuestos de azalactama como inhibidores de hpk1 | |
| AR109729A1 (es) | Método para producir la forma cristalina de modificación a de calcobutrol | |
| CO2022000084A2 (es) | Compuestos para tratar enfermedad respiratoria | |
| AR075425A1 (es) | Procedimiento de preparacion e intermediarios | |
| AR110198A1 (es) | Síntesis de un compuesto que modula la actividad de proteínas que contienen bromodominio | |
| PT4132909T (pt) | Sais de adição de ácido orgãnicos de s-pindolo | |
| ES2537221B2 (es) | SALES DE PIRIDAZINO[2,3-a]PIRROLO[2,1-c]QUINOXALINIO PARA EL TRATAMIENTO DE INFECCIONES POR LEISHMANIA Y ENFERMEDADES EN LAS QUE ESTÁ IMPLICADA LA PROTEÍNA TIROSINA FOSFATASA 1B | |
| BR112021018357A2 (pt) | Forma cristalina de inibidor de fosfodiesterase, método de preparação para a mesma e uso da mesma | |
| CL2022002037A1 (es) | Uso de un compuesto inhibidor de fgfr; forma sólida amorfa; proceso para preparar el compuesto (div. sol. n° 202002839). | |
| PE20140777A1 (es) | Metodo de obtencion de una composicion farmaceutica de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio para el tratamiento de enfermedades cardiovasculares |